Robert N J, Martin L, Taylor C D, Popkin J, Parkinson D R, White C, Pappas C A, Tamura H, Gelman R, Cohen J
Division of Hematology/Oncology, New England Medical Center, Boston, MA 02111.
Breast Cancer Res Treat. 1990 Oct;16(3):273-8. doi: 10.1007/BF01806335.
We have previously described an in vitro immunohistochemical test employing anti-receptor antibodies, for demonstrating the nuclear binding characteristics of estrogen receptors (ER) in breast carcinomas. Based on a retrospective analysis of twenty-five patients with estrogen receptor-positive (ER+) breast cancer who were treated with hormone therapy and whose clinical responses were evaluable, we were able to demonstrate that this test may be valuable to predict which, among the ER+ tumors (whether or not they are progesterone receptor positive, PR+), are likely to respond to hormone therapy and which may fail. While tumors in which ER exhibited abnormalities in nuclear binding behavior (ligand-independent nuclear binding or no nuclear binding) failed hormone therapy (16 out of 19 patients), those in which nuclear binding of ER appeared normal (ligand-dependent) in the in vitro test, responded to hormone therapy (5/6 patients). While our previous report dealt with the procedural details, specificity of the reagents, and the design of the study, this report addresses the clinical aspects of this study and response correlation.
我们之前描述了一种采用抗受体抗体的体外免疫组织化学检测方法，用于证明乳腺癌中雌激素受体（ER）的核结合特性。基于对25例接受激素治疗且临床反应可评估的雌激素受体阳性（ER+）乳腺癌患者的回顾性分析，我们能够证明该检测对于预测哪些ER+肿瘤（无论它们是否为孕激素受体阳性，PR+）可能对激素治疗有反应以及哪些可能无效可能是有价值的。在ER表现出核结合行为异常（非配体依赖性核结合或无核结合）的肿瘤中，激素治疗失败（19例患者中有16例），而在体外检测中ER核结合表现正常（配体依赖性）的肿瘤对激素治疗有反应（6例患者中有5例）。我们之前的报告涉及程序细节、试剂的特异性和研究设计，而本报告则探讨了该研究的临床方面以及反应相关性。
